Understand that stress is caused not by other people or external events, but by your reactions to them. s.hbr.org/3E8pQvl

SComatic identifies somatic mutations from scRNA-seq and scATAC data without a matched reference sample go.nature.com/44brDLt

Congratulations to Dr Marcela Maus, MD, PhD, and @SRBailey32, PhD, et al., recipients of this year’s Blood Cancer Discovery Award for Outstanding Journal Article! Learn more about this award: bit.ly/45ugQfQ Mass General Cancer Center Harvard Medical School

Join us in #Boston! Don't miss the chance to listen and ask questions to #myeloma specialists from Dana-Farber: . , Catherine Marinac, PhD, Omar Nadeem and Elizabeth (Betsy) O'Donnell, MD. Register here: buff.ly/3Xtm7kA

Hi #MedTwitter! I'm Annie, MS4 Mayo Clinic Alix School of Medicine and I am pumped to be applying #IM for #Match2024! I am passionate about #hemeonc 🩸, #palliative 🫂 , & #research 🔬 - if you can't find me running stats on an #mmsm trial or rounding in the ICU, I'm probably playing soccer ⚽

As always, stellar work by nizar jacques bahlis and team. This is key to understanding resistance to T-cell therapies based on the integrity (or lack) of the target (BCMA or GPRC5D). Consistent with clonal selection. Superb science in Nature Medicine. Kudos! 👏 #mmsm #MedTwitter

BREAKING NEWS!⁦ Nature Medicine⁩ study shows mechanisms of resistance to BCMA- or GPRC5D-targeted immunotherapies in myeloma #mmsm@hollyleeYJ Francesco Maura nizar jacques bahlis ⁦International Myeloma Foundation⁩ Multiple Myeloma RF⁩ ⁦@HealthtreeMM⁩ ⁦Sylvester Comprehensive Cancer Center⁩ nature.com/articles/s4159…

Carl June on The #Boundless #Potential of #CAR_T Cell Therapy Society for Immunotherapy of Cancer AACR ASCO pennmedicine.org/news/news-blog… via Penn Medicine

Exciting preprint to share! With Diko Kazandjian, C. Ola Landgren, M.D. , Francesco Maura. Genomic profiling of high-risk smoldering multiple myeloma (HR-SMM) to contextualize the generally favorable results in trials of early tx intervention. tinyurl.com/2c58vmza #mmsm (1/n)

Thanks for reading! Big thanks to everyone who made this possible including Diko Kazandjian C. Ola Landgren, M.D. @francescomaura4 of Sylvester Comprehensive Cancer Center Patrick Blaney Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Faith E Davies Gareth Morgan and the ADuong team . Gad Getz Laboratory Romanos SP (16/16)

The all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects. Read the full study results: nej.md/3sDc40Z

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the FDA for the treatment of #MultipleMyeloma. ms.spr.ly/60189VC7u #BloodCancerAwarenessMonth

Check out our latest preprint paper: Novel insights on how genomic profiling of high-risk smoldering multiple myeloma patients influences treatment outcomes. Better profiling is urgently needed! #mmsm International Myeloma Foundation Multiple Myeloma RF @HealthtreeMM Sylvester Comprehensive Cancer Center ASH The Leukemia & Lymphoma Society

Investigators in multiple myeloma discussed new therapies, optimal sequencing, the role of MRD, CAR T-cell therapy & more! Dana-Farber Winship Cancer Institute of Emory University Stanford Cancer Institute MD Anderson Cancer Center . Surbhi Sidana, MD Krina Patel ow.ly/KjP450PG3Jy

📣 BREAKING NEWS 📣 We're excited to announce the 12 teams shortlisted for a #CancerGrandChallenges award. Each team has the chance to receive up to $25m to make radical progress against cancer’s toughest challenges. Discover the teams: bit.ly/3YYV5lS National Cancer Institute Cancer Research UK

Meet this 12 teams that were shortlisted for the 2023 Cancer Grand Challenges. We look forward to great things from these groups! cancergrandchallenges.org/shortlist

After 7 (!!!) proctored exams, and one ongoing "Longitudinal Knowledge Assessment", I have plenty of experience with the ABIM tests. Some thoughts -- and wondering, is it time for a change? blogs.jwatch.org/hiv-id-observa… 1/2

We are Dana-Farber strong! #MOretreat23 with the best of the best!

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 3 🇪🇺🇨🇾🇺🇸🇬🇧🇨🇦🇰🇪 oncodaily.com/positive/9118.… On August 26th, OncoDaily began featuring '100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2023.' As we

📢Clonal hematopoiesis driven by mCAs📢What fitness effects do mCAs confer to our blood cells?🩸 How often do they occur? Does an mCA’s fitness correlate with blood cancer risk?🔎Read mine & Jamie Blundell's latest paper Nature Genetics to find out (& more!):👉🔗rdcu.be/dlRRr